Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope [0.03%]
英国风湿病学会针对炎症性关节炎中生物制剂和靶向合成DMARD安全性的指南范围
Stephanie F Ling,Joshua L Bennett,Vanessa J Reid et al.
Stephanie F Ling et al.
This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis (IA) across the life course. Important updates from the 2019 ite...
Paediatric relapsing polychondritis coexisting with Sjögren's disease in a 10-year-old girl successfully treated with mycophenolate mofetil [0.03%]
美洛昔康治疗共存有干燥综合征的10岁复发性多软骨炎患儿一例报告
Takahiro Matsuoka,Takeshi Yamamoto,Toshiyuki Kobayashi et al.
Takahiro Matsuoka et al.
Identifying axial spondyloarthritis flares using the Evaluation of Ankylosing Spondylitis Quality of Life (EASiQoL) patient-reported outcome measure via an online portal: the FASTER study protocol [0.03%]
利用在线门户通过评估强直性脊柱炎生活质量(EASiQoL)患者报告结局工具识别轴向脊柱关节炎急性发作：FASTER研究方案
James A Prior,Helen Parsons,Kirstie L Haywood et al.
James A Prior et al.
Background: People with axial spondyloarthritis (axSpA) frequently experience increases in symptoms (flares) related to pain, stiffness and fatigue. Despite frequent use of the term 'flare' within axSpA, it is poorly defi...
Association between gout, hyperuricaemia and Parkinson's disease risk: a cohort study in western Sweden (2001-2017) [0.03%]
一项基于瑞典西部（2001-2017年）人群的队列研究：痛风、高尿酸血症与帕金森病风险之间的关联
Mats Dehlin,Filip Bergquist,Panagiota Drivelegka et al.
Mats Dehlin et al.
Objectives: Neurodegenerative diseases including Parkinson's disease (PD) have been found to be associated with gout and hyperuricaemia in multiple studies but with conflicting results. We set out to determine the inciden...
HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial [0.03%]
HANDSCAN缓解标准对比ACR/EULAR布尔缓解标准作为早期类风湿关节炎治疗目标：一项随机对照试验结果
Matthijs S van der Leeuw,Paco M J Welsing,Janneke Tekstra et al.
Matthijs S van der Leeuw et al.
Objectives: The HandScan is a novel method to quickly and objectively quantify RA disease activity using optical spectral transmission in hands and wrists. The aim of this study was to investigate whether treat-to-target ...
Bone marrow oedema of the sacroiliac joint without spondyloarthritis: a retrospective study of 34 cases of osteitis condensans ilii [0.03%]
无脊柱关节炎的骶髂关节骨髓水肿：34例髂骨浓密性骨炎病例回顾性研究
Sabine Guehery,Julian Plenard,François Lafourcade et al.
Sabine Guehery et al.
Objective: To determine the prevalence of bone marrow oedema (BME) in osteitis condensans ilii (OCI) on MRI of the sacroiliac joint (SIJ). Secondary objectives include comparisons of socio-demographic characteristics, pre...
Let's ask the patient: disease prediction based on patients' symptom descriptions in free text [0.03%]
基于患者自由文本症状描述的疾病预测方法研究
Inés Pérez-Sancristóbal,Nils Steinz,Ling Qin et al.
Inés Pérez-Sancristóbal et al.
Objective: This study evaluates the value self-reported free-text symptom descriptions for supporting diagnostic decisions in osteoarthritis (OA), fibromyalgia (FM) and immune-mediated rheumatic diseases (imRD) using natu...
Early onset neutropenia in rituximab treated rheumatoid arthritis patients: a case series [0.03%]
利妥昔单抗治疗的类风湿关节炎患者早期出现中性粒细胞减少症：一系列病例报告
Chung Mun Alice Lin,Alice R Lorenzi,John D Isaacs et al.
Chung Mun Alice Lin et al.
Patient and caregiver perspectives of an early integrated systemic sclerosis palliative care clinic: a qualitative study [0.03%]
系统性硬化症综合姑息治疗门诊的患者和护理人员视角：定性研究
Carolyn Wicks,Julie McDonald,Laura Ross
Carolyn Wicks
Objectives: Individuals with systemic sclerosis (SSc) and their caregivers have unmet palliative care needs, yet the role of palliative medicine in SSc is unclear. In this study we aimed to explore patient and caregiver p...
Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study [0.03%]
Guselkumab真实世界有效性研究：意大利多中心观察结果
Andrea Becciolini,Antonio Marchesoni,Simone Parisi et al.
Andrea Becciolini et al.
Objectives: Guselkumab is a biologic disease-modifying antirheumatic drug (bDMARD) with proven efficacy for psoriatic arthritis (PsA) in randomized controlled trials. Evidence of its effectiveness from clinical practice r...